About: Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.78 (-5.32%)
ELTX NASDAQ Elicio Therapeutics Inc.
Elicio Therapeutics Inc. share price
ELTX price activity
Last Price
$1.780
Change (24hr)
-0.10 USD (-5.32%)
Volume
112.36K
Volume (4w avg)
-
Open
$1.88
Day Range
$1.78 - $1.88
Previous Close
$1.88
Last Trade
13 Oct, 4:21 pm GMT+0
Delayed
13 Oct, 4:21 pm GMT+0
ELTX price performance
Delayed
13 Oct, 4:21 pm GMT+0
ELTX Market Signals